Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420327 · ClinicalTrials.gov registry record · NA
Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
A NA study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT02420327: Completed NA study, sponsored by University of Maryland, Baltimore.
NCT02420327 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02420327, a NA study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimer's disease. This proof-of-principle study is performed in healthy non-smokers and involves two single exposures to a nicotine patch (7 mg/24 hrs) and two single exposures to galantamine (4 mg). The dose of galantamine is substantially lower than the clinical dose range of 16-24 mg/day. The hypothesis is that performance-enhancing effects of nicotine are greater in the presence of this low dose of galantamine.
Primary Outcome
The task requires detecting brief target stimuli presented at one of four locations in the four corner of the screen. On predictive trials, a central cue predicts the target location.
Interventions
- DRUG Placebo patch & placebo capsule
- DRUG Placebo patch & galantamine capsule
- DRUG Nicotine patch & placebo capsule
- DRUG Nicotine patch and galantamine capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-03 |
| Phase | NA |
What the finished NCT02420327 record still lists
NCT02420327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo patch & placebo capsule is the first listed.
NCT02420327 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02420327 about?
NCT02420327 is a clinical study titled "Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine". The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimer's disease. This proof-of-principle study is performed in healthy non-smokers and involves two single exposures to a nicot...
What is the current status of trial NCT02420327?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2014-09. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02420327?
The interventions under investigation include: Placebo patch & placebo capsule (DRUG), Placebo patch & galantamine capsule (DRUG), Nicotine patch & placebo capsule (DRUG), Nicotine patch and galantamine capsule (DRUG).
Who is sponsoring clinical trial NCT02420327?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02420327's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia